Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE:NVO) following recent industry developments ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback